A clinical trial showed that Poly-ICLC (Hiltinol), an advanced form of TLR3 agonist, could kill cancer cells and inhibit the metastasis of non-small cell lung cancer by activating several cancer suppressors and rebuilding an immunosuppressive tumor microenvironment (17). Here, TLR3 is linked to neoplasm.